Wits University has launched its second Covid-19 vaccine trial, testing an experimental shot made by US biotech company Novavax, supported in part by a $15m (about R261m) grant from the Bill & Melinda Gates Foundation.

The phase 2b trial of the shot called NVX-CoV2373 will enrol about 2,900 adult volunteers, including 240 who are HIV positive. It will evaluate the shot’s safety and ability to stimulate the body’s immune system to protect against future infection with Sars-CoV-2, the virus that causes Covid-19.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now